Replies to post #218773 on Biotech Values

[DewDiligence]

Speaking of wet AMD…NVS used a priority-review voucher for brolucizumab (RTH258), allowing a launch in late 2019 (pending FDA approval):

https://www.novartis.com/news/media-releases/novartis-announces-fda-filing-acceptance-and-priority-review-brolucizumab-rth258-patients-wet-amd